ASX:TTB

Stock Analysis Report

Executive Summary

Total Brain Limited develops and sells brain health products in the United States.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Share Price & News

How has Total Brain's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.0%

TTB

3.3%

AU Healthcare

2.5%

AU Market


1 Year Return

41.7%

TTB

18.0%

AU Healthcare

11.1%

AU Market

Return vs Industry: TTB exceeded the Australian Healthcare industry which returned 18% over the past year.

Return vs Market: TTB exceeded the Australian Market which returned 11.1% over the past year.


Shareholder returns

TTBIndustryMarket
7 Day2.0%3.3%2.5%
30 Day-10.5%4.1%0.7%
90 Day96.2%0.8%1.4%
1 Year42.2%41.7%21.7%18.0%17.5%11.1%
3 Year-55.5%-55.7%5.0%-4.6%37.8%19.4%
5 Year-78.7%-78.8%48.2%27.3%51.7%17.6%

Price Volatility Vs. Market

How volatile is Total Brain's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Total Brain undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: TTB (A$0.05) is trading below our estimate of fair value (A$0.22)

Significantly Undervalued: TTB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TTB is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: TTB is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate TTB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TTB is overvalued based on its PB Ratio (2x) compared to the AU Healthcare industry average (1.5x).


Next Steps

Future Growth

How is Total Brain forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

77.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TTB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: TTB is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: TTB's loss is forecast to worsen by 0% next year.

Revenue vs Market: TTB's revenue (59.5% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: TTB's revenue (59.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: TTB's Return on Equity is forecast to be low in 3 years time (10%).


Next Steps

Past Performance

How has Total Brain performed over the past 5 years?

-38.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: TTB is unprofitable, and losses have increased over the past 5 years at a rate of -38.6% per year.

Accelerating Growth: Unable to compare TTB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TTB is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-1.7%).


Return on Equity

High ROE: TTB has a negative Return on Equity (-42.39%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: TTB is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: TTB is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Total Brain's financial position?


Financial Position Analysis

Short Term Liabilities: TTB's short term assets (A$6.2M) exceeds its short term liabilities (A$1.1M)

Long Term Liabilities: TTB's short term assets (6.2M) exceeds its long term liabilities (98.9K)


Debt to Equity History and Analysis

Debt Level: TTB is debt free.

Reducing Debt: TTB has no debt compared to 5 years ago when its debt to equity ratio was 57.1%.


Balance Sheet

Inventory Level: TTB has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if TTB's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TTB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: TTB has less than a year of cash runway if free cash flow continues to reduce at historical rates of -37.9% each year


Next Steps

Dividend

What is Total Brain's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.5%markettop25%5.6%industryaverage2.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate TTB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TTB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if TTB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TTB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TTB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Total Brain's salary, the management and board of directors tenure and is there insider trading?

2.2yrs

Average management tenure


CEO

Louis Gagnon 0

2.4yrs

Tenure

AU$662,443

Compensation

Mr. Louis Gagnon has been Chief Executive Officer of Brain Resource Limited since May 22, 2017 and has been its Managing Director since December 22, 2017. Mr. Gagnon served as Chief Product and Marketing O ...


CEO Compensation Analysis

Compensation vs. Market: Louis has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Australian market.

Compensation vs Earnings: Louis's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.2yrs

Average Tenure

Experienced Management: TTB's management team is considered experienced (2.2 years average tenure).


Board Age and Tenure

1.6yrs

Average Tenure

Experienced Board: TTB's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyAU$110,26515 Oct 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares2,202,102
Max PriceAU$0.05
SellAU$226,49502 Oct 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares3,864,569
Max PriceAU$0.059
BuyAU$73,48002 Oct 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares1,527,103
Max PriceAU$0.048
BuyAU$118,46902 Sep 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares3,725,014
Max PriceAU$0.035
SellAU$350,82227 May 19
Morgan Stanley, Investment Banking and Brokerage Investments
EntityCompany
Shares11,897,873
Max PriceAU$0.03
BuyAU$8,30022 May 19
Matthew Morgan
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares296,429
Max PriceAU$0.028
SellAU$97509 May 19
Ozado Partners LLC
EntityCompany
Shares36,090
Max PriceAU$0.027
BuyAU$157,49918 Apr 19
Sun Hung Kai & Co. Limited, Asset Management Arm
EntityCompany
Shares5,625,000
Max PriceAU$0.028
SellAU$3,79226 Mar 19
Sculptor Capital Management, Inc.
EntityCompany
Shares135,412
Max PriceAU$0.028
BuyAU$8,55813 Feb 19
Matthew Morgan
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares315,111
Max PriceAU$0.027
BuyAU$8,53020 Dec 18
Matthew Morgan
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares284,320
Max PriceAU$0.03
BuyAU$4,69816 Nov 18
Matthew Morgan
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares134,219
Max PriceAU$0.035

Ownership Breakdown


Management Team

  • Dan Segal

    Consultant

    • Tenure: 3yrs
    • Compensation: AU$238.40k
  • Evian Gordon

    Founder & Executive Chairman

    • Tenure: 0yrs
    • Compensation: AU$537.36k
  • Marcel Legrand

    Head of Revenue & Corporate Development

    • Tenure: 2.2yrs
  • Phillip Hains

    Joint Company Secretary

    • Tenure: 1.3yrs
  • Louis Gagnon

    MD, CEO & Director

    • Tenure: 2.4yrs
    • Compensation: AU$662.44k
  • Matt Mund

    Chief Operating Officer

    • Tenure: 2.2yrs
    • Compensation: AU$412.12k
  • Emil Vasilev

    Director of Finance & Operations

    • Tenure: 2.4yrs
    • Compensation: AU$298.94k
  • Matt Resteghini

    Chief Marketing Officer

    • Tenure: 1.7yrs
  • Harvey Bui

    Joint Company Secretary

    • Tenure: 1.3yrs

Board Members

  • Evian Gordon

    Founder & Executive Chairman

    • Tenure: 0yrs
    • Compensation: AU$537.36k
  • Matt Morgan (45yo)

    Non-Executive Director

    • Tenure: 3.6yrs
    • Compensation: AU$283.40k
  • Louis Gagnon

    MD, CEO & Director

    • Tenure: 2.4yrs
    • Compensation: AU$662.44k
  • Ajay Arora

    Non-Executive Director

    • Tenure: 1.4yrs
  • David Torrible

    Non-Executive Director

    • Tenure: 0.3yrs

Company Information

Total Brain Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Total Brain Limited
  • Ticker: TTB
  • Exchange: ASX
  • Founded: 2000
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$41.217m
  • Shares outstanding: 777.69m
  • Website: https://www.totalbrain.com

Number of Employees


Location

  • Total Brain Limited
  • 268 Bush Street
  • Suite 2633
  • San Francisco
  • California
  • 94104
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TTBASX (Australian Securities Exchange)YesOrdinary SharesAUAUDAug 2001
TTBCHIA (Chi-X Australia)YesOrdinary SharesAUAUDAug 2001
BRRZ.YOTCPK (Pink Sheets LLC)SPONSORED ADSUSUSDApr 2011

Biography

Total Brain Limited develops and sells brain health products in the United States. It offers Total Brain, a neuroscience-based mental health and fitness platform. The company was formerly known as Brain Re ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 10:33
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.